NOVABRIDGE BIOSCIENCES (NBP) Stock Price & Overview
NASDAQ:NBP • US44975P1030
Current stock price
The current stock price of NBP is 2.58 USD. Today NBP is up by 0.39%. In the past month the price increased by 2.38%.
NBP Key Statistics
- Market Cap
- 297.387M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.42
- Dividend Yield
- N/A
NBP Stock Performance
NBP Stock Chart
NBP Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NBP.
NBP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NBP. NBP has a great financial health rating, but its profitability evaluates not so good.
NBP Earnings
NBP Forecast & Estimates
9 analysts have analysed NBP and the average price target is 8.57 USD. This implies a price increase of 232.09% is expected in the next year compared to the current price of 2.58.
NBP Groups
Sector & Classification
NBP Financial Highlights
Over the last trailing twelve months NBP reported a non-GAAP Earnings per Share(EPS) of -0.42. The EPS increased by 58.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.76% | ||
| ROE | -20.03% | ||
| Debt/Equity | 0 |
NBP Ownership
NBP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.52 | 354.636B | ||
| AMGN | AMGEN INC | 15.15 | 186.69B | ||
| GILD | GILEAD SCIENCES INC | 15.03 | 164.958B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.47 | 111.326B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.92 | 78.928B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.5 | 41.441B | ||
| INSM | INSMED INC | N/A | 31.186B | ||
| NTRA | NATERA INC | N/A | 29.449B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.041B | ||
| BIIB | BIOGEN INC | 11.79 | 27.895B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.65 | 25.171B | ||
| MRNA | MODERNA INC | N/A | 22.05B | ||
| INCY | INCYTE CORP | 12.5 | 19.252B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NBP
Company Profile
NovaBridge Biosciences operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company is headquartered in Rockville, Maryland and currently employs 32 full-time employees. The company went IPO on 2020-01-17. The firm combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.
Company Info
IPO: 2020-01-17
NOVABRIDGE BIOSCIENCES
Suite 400, 2440 Research Blvd
Rockville MARYLAND US
Employees: 32
Phone: 13016702800
NOVABRIDGE BIOSCIENCES / NBP FAQ
Can you describe the business of NOVABRIDGE BIOSCIENCES?
NovaBridge Biosciences operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company is headquartered in Rockville, Maryland and currently employs 32 full-time employees. The company went IPO on 2020-01-17. The firm combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.
What is the current price of NBP stock?
The current stock price of NBP is 2.58 USD. The price increased by 0.39% in the last trading session.
What is the dividend status of NOVABRIDGE BIOSCIENCES?
NBP does not pay a dividend.
What is the ChartMill rating of NOVABRIDGE BIOSCIENCES stock?
NBP has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of NOVABRIDGE BIOSCIENCES (NBP) based on its PE ratio?
NOVABRIDGE BIOSCIENCES (NBP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.42).
What is the market capitalization of NBP stock?
NOVABRIDGE BIOSCIENCES (NBP) has a market capitalization of 297.39M USD. This makes NBP a Micro Cap stock.
Who owns NOVABRIDGE BIOSCIENCES?
You can find the ownership structure of NOVABRIDGE BIOSCIENCES (NBP) on the Ownership tab.